Abcellera Biologics Inc (ABCL) — Cash Flow Reinvestment Rate
Abcellera Biologics Inc (ABCL) has a Cash Flow Reinvestment Rate of 1.89x as of June 2023, reinvesting $37.52 Million (capex $27.35 Million plus investments $-10.17 Million) from operating cash flow of $19.82 Million. See Abcellera Biologics Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Abcellera Biologics Inc Cash Flow Reinvestment Rate (2018–2022)
Historical reinvestment intensity for Abcellera Biologics Inc across 5 annual periods. For the full cash flow conversion analysis, see Abcellera Biologics Inc cash flow conversion.
Annual Cash Flow Reinvestment Rate for Abcellera Biologics Inc (2018–2022)
Year-by-year capital reinvestment analysis for Abcellera Biologics Inc. See Abcellera Biologics Inc (ABCL) flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 1.53x | $425.29 Million | $277.36 Million | $72.66 Million | ▲ +11.7% |
| 2021 | 1.37x | $335.88 Million | $244.58 Million | $58.45 Million | ▼ -8.1% |
| 2020 | 1.49x | $33.92 Million | $22.69 Million | $14.67 Million | ▼ -58.8% |
| 2019 | 3.63x | $9.78 Million | $2.69 Million | $4.00 Million | ▲ +21.9% |
| 2018 | 2.98x | $10.61 Million | $3.56 Million | $5.31 Million | — |